{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:30Z","timestamp":1793316330097,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jhep.2021.06.037","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T02:56:11Z","timestamp":1625626571000},"page":"1083-1095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0687-5273","authenticated-orcid":false,"given":"Heather P.","family":"Llewellyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Arat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Kalabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4078-1054","authenticated-orcid":false,"given":"Elias","family":"Oziolor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Virgen-Slane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4671-1639","authenticated-orcid":false,"given":"Timothy","family":"Affolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.06.037_bib1","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 Inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Canc Res"},{"key":"10.1016\/j.jhep.2021.06.037_bib2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jhep.2021.06.037_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2021.06.037_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.06.037_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.06.037_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.jhep.2021.06.037_bib7","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2021.06.037_bib8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.06.037_bib9","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.06.037_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.3010","article-title":"Preliminary results from a phase 1\/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma","volume":"32","author":"Gibney","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2021.06.037_bib11","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2015.02.038","article-title":"The yin and yang of evasion and immune activation in HCC","volume":"62","author":"Makarova-Rusher","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.06.037_bib12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.06.037_bib13","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.4049\/jimmunol.0904173","article-title":"Ability of IDO to attenuate liver injury in alpha-galactosylceramide-induced hepatitis model","volume":"185","author":"Ito","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2021.06.037_bib14","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.4049\/jimmunol.1200819","article-title":"Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO","volume":"189","author":"Sumpter","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2021.06.037_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073404","article-title":"Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation","volume":"8","author":"Nagano","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2021.06.037_bib16","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.jhep.2021.06.037_bib17","article-title":"Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in\u00a0vitro functional studies, and cynomolgus macaque toxicology","volume":"11","author":"Selby","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2021.06.037_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217276","article-title":"Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice","volume":"14","author":"Affolter","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.jhep.2021.06.037_bib19","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.4049\/jimmunol.179.8.5064","article-title":"PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues","volume":"179","author":"Keir","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2021.06.037_bib20","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.4049\/jimmunol.1201617","article-title":"Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner","volume":"190","author":"Charlton","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2021.06.037_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1158\/2326-6066.CIR-14-0118","article-title":"Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector\/memory CD8 T cells in a poorly immunogenic tumor model","volume":"3","author":"Chen","year":"2015","journal-title":"Canc Immunol Res"},{"key":"10.1016\/j.jhep.2021.06.037_bib22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/hep.29802","article-title":"Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort","volume":"69","author":"Church","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.06.037_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/1354750X.2016.1269131","article-title":"A\u00a0longitudinal assessment of miR-122 and GLDH as biomarkers of drug-induced liver injury in the rat","volume":"22","author":"Thulin","year":"2017","journal-title":"Biomarkers"},{"key":"10.1016\/j.jhep.2021.06.037_bib24","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2021.06.037_bib25","doi-asserted-by":"crossref","first-page":"6868","DOI":"10.4049\/jimmunol.180.10.6868","article-title":"Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses","volume":"180","author":"de la Rosa","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2021.06.037_bib26","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41590-019-0523-x","article-title":"Monocytes work harder under pressure","volume":"20","author":"Tolar","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2021.06.037_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nbt.2859","article-title":"The\u00a0dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells","volume":"32","author":"Trapnell","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2021.06.037_bib28","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2021.06.037_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3001","article-title":"Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature","volume":"33","author":"Ribas","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2021.06.037_bib30","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br J Canc"},{"key":"10.1016\/j.jhep.2021.06.037_bib31","article-title":"IL-18 receptor marks functional CD8(+) T cells in non-small cell lung cancer","volume":"6","author":"Timperi","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jhep.2021.06.037_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/14712598.2020.1738379","article-title":"Rationale for IL-15 superagonists in cancer immunotherapy","volume":"20","author":"Knudson","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jhep.2021.06.037_bib33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrrheum.2016.131","article-title":"Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?","volume":"12","author":"van der Vlist","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jhep.2021.06.037_bib34","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-17-1847","article-title":"Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway","volume":"24","author":"Bartkowiak","year":"2018","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.jhep.2021.06.037_bib35","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.4049\/jimmunol.1402521","article-title":"Batf2\/Irf1 induces inflammatory responses in classically activated macrophages, lipopolysaccharides, and mycobacterial infection","volume":"194","author":"Roy","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2021.06.037_bib36","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.4049\/jimmunol.178.7.4194","article-title":"Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice","volume":"178","author":"Niu","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2021.06.037_bib37","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.jhep.2021.06.037_bib38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.imlet.2005.06.001","article-title":"Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease","volume":"101","author":"Lee","year":"2005","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jhep.2021.06.037_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cells7080108","article-title":"Chemokine receptors and exercise to tackle the inadequacy of T cell homing to the tumor site","volume":"7","author":"Idorn","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2021.06.037_bib40","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","article-title":"Pathologic changes in ipilimumab-related hepatitis\u00a0in patients with metastatic melanoma","volume":"57","author":"Kleiner","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2021.06.037_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhep.2021.06.037_bib42","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821018870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821018870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:43:07Z","timestamp":1759174987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821018870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0168827821018870"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.06.037","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}